Personalised medicine has been a goal of researchers and doctors for a long time. Now, researchers have developed what they call a personalised Therapeutic Intervention Fingerprint (pTIF), for patients with neurological disease.
Scientists are taking advantage of the “self-homing” abilities of cancer cells and are creating armies of cancer-killing cells using CRISPR gene-editing.
Scientists have discovered a “big bang” of Alzheimer’s disease — the precise point at which a healthy protein becomes toxic but has not yet formed deadly tangles in the brain.
A new technique for precisely targeting molecules within cells is paving the way for safer medicines that are free of side effects.
The US Health and Human Services Secretary Alex Azar has approved adding a test for spinal muscular atrophy to the list of recommended newborn screens in the United States.
People living in England will be the first in the world to have access to DNA tests as routine care starting this fall, putting the NHS at the forefront of healthcare, as it takes a huge step towards precision medicine.
The “Born in Guangzhou Cohort Study” is looking to recruit 50,000 baby-mother sets by 2020. Since 2012, 1.6 million samples have been collected for the project and the some of the first findings have been published.
Studies of breast cancer do not take sufficient account of patients’ race, ethnicity, economic status, education level, health insurance coverage, and other social factors, a group of scientists argue.
Cancer Research UK Cambridge Institute is pushing for the use of genetic testing to transform treatment of breast cancer with the Personalised Breast Cancer Programme.
The California State Legislature has approved a budget including $2 million for a pilot project to fund clinical whole genome sequencing as a first line diagnostic test.
To understand the biology of diseased organs, researchers can use different types of molecular data. One of the biggest computational challenges at the moment is integrating these multiple data types.
The Swiss drugmaker has clearly noticed the genomic profiling group’s ability to personalise cancer care, now that it will take complete ownership of the company.